Nuvaira Announces 1st Patient Treated in RELIEF-1 Study Evaluating New Approach for Asthma Treatment
Clinical Trial Assesses First-of-its-Kind, One-Time Medical Procedure in Patients with Severe Asthma
MINNEAPOLIS, March 27, 2018 (GLOBE NEWSWIRE) -- Nuvaira, a developer of medical devices to treat obstructive lung diseases, today announced treatment of the first patient in the RELIEF-1 Clinical Study in Europe. The RELIEF-1 trial (NCT02872298) is a prospective, multi-center, single-arm (non-randomized) study designed to evaluate the safety and technical feasibility of a procedure called Targeted Lung Denervation (TLD) using the Nuvaira(TM) Lung Denervation System for the treatment of severe asthma.
The feasibility study is slated to treat a total of 30 patients at facilities in France, Germany, the Netherlands and the United Kingdom, with patient follow-up planned out to three years. Principal Investigators of RELIEF-1 are Nick ten Hacken, M.D., Ph.D., at the University Medical Center Groningen (UMCG), the Netherlands, and Professor Pallav Shah, M.D., at Royal Brompton & Harefield NHS Foundation Trust and Chelsea and Westminster Hospital NHS Foundation Trust in London. Dirk-Jan Slebos, M.D., Ph.D., performed the first patient treatment in the Department of Pulmonary Diseases at UMCG.
"The first patient tolerated the minimally invasive therapeutic treatment very well and there were no procedural complications," according to Dr. ten Hacken. "TLD is the first medical procedure that targets the whole lung by disrupting the overactive nerves into the lungs, thereby opening up the airways and making it easier to breathe. We are encouraged by how well the first patient responded to TLD and we look forward to treating additional asthma patients utilizing this innovative, one-time procedure."
The Nuvaira Lung Denervation System is a catheter-based system developed to treat patients with obstructive lung disease, specifically severe asthma and chronic obstructive pulmonary disease (COPD). The system's proprietary technology delivers targeted energy to disrupt nerve signals to the lungs using a process known as denervation. The simple, one-time bronchoscopic treatment has the potential to provide lasting whole lung improvement for severe asthma patients by opening obstructed airways to make breathing easier. Currently, there is no cure for asthma, but there are treatment plans that can help patients manage the disease. Approximately three quarters of asthma sufferers are adults, with 10 percent suffering from severe asthma, which is difficult to treat.
"The first patient treatment in our RELIEF-1 Clinical Trial is an important milestone in our quest to develop a safe and effective treatment for asthma patients worldwide," said Dennis Wahr, M.D., chief executive officer at Nuvaira. "Earlier trials evaluating TLD in COPD patients have demonstrated feasibility and promising long-term, sustained treatment results. We look forward to the completion of this important study."
Asthma is among the most prevalent chronic respiratory diseases, estimated to affect over 300 million people globally. Asthma sufferers have difficulty moving air in and out of the lungs, due to airway narrowing (bronchoconstriction), airway wall thickening (inflammation), and elevated mucus production. The ongoing burden of this serious and costly disease is estimated at more than $50 billion per year with more than 5,000 emergency department visits per day in the US alone,. Severe asthma often requires multiple medications to maintain or achieve control of symptoms and the risk of flare-ups. Severe asthma may also be refractory, or insensitive to currently available medications. This means that despite use of their medications, these patients still cannot achieve asthma control or avoid flare-ups, which may result in an overall reduction in their quality of life.
Nuvaira (formerly known as Holaira) is a privately held company headquartered in Minneapolis, Minn. The company is developing the Nuvaira(TM) Lung Denervation System to address chronic obstructive pulmonary disease (COPD) and asthma by treating the overactive airway nerves during Targeted Lung Denervation* (TLD). Nuvaira received CE Mark approval for its Nuvaira Lung Denervation System for the treatment of COPD in January 2016. More information may be found at www.Nuvaira.com.
*Targeted Lung Denervation (TLD) is currently under clinical investigation for asthma and COPD and is not yet commercially available.
Nuvaira is a trademark of Nuvaira, Inc.
 G John Gibson, Robert Leddenkemper, Yves Sibille, Bo Lundback. European Lung White Book: Respiratory Health and Disease in Europe. European Respiratory Society, 2013.
 Global, regional prevalence for COPD and asthma 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. www.the lancert.com/respiratory. Online Aug. 16, 2017.
 Wang, Emergency department charges for asthma-related outpatient visits. J Health Care Poor Underserved. 2014 February; 25(1):396-405
 Barnett, Costs of Asthma in the United States:2002-2007. J Allergy Clin Immunol January 2011.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/b9fcef4f-e7c0-44d9-8bae-fed2aa8b1c66
Media Inquiries: Amy Wolter +1 (763) 450-5676 email@example.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nuvaira, Inc via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Cority Recognized by Independent Analyst Firm as a “Powerhouse Vendor” – Moving Up Once Again as a Leader in The Green Quadrant EHS Software 201926.3.2019 15:10:00 CET | Pressemelding
Toronto, ON, March 26, 2019 (GLOBE NEWSWIRE) -- Cority, the most trusted provider of environmental, health, safety, and quality (EHSQ) software, today announced it has been recognized as an Environmental, Health, and Safety (EHS) software Leader for the third consecutive year in the latest benchmark report by independent research firm Verdantix. The Green Quadrant EHS Software 2019 provides a detailed fact-based comparison of the 23 most prominent EHS software vendors in the industry. Based on the proprietary Verdantix Green Quadrant methodology, Cority moved up the Leaders’ quadrant significantly, placing among the top vendor scores on its software application capabilities and market momentum. The results underscore Cority’s solid position in a differentiated top-tier of enterprise-scale vendors. “Cority has established itself as an enterprise-scale EHS information management powerhouse vendor,” said Yaowen Ma, Senior Analyst, Verdantix. “Cority should be shortlisted by buyers seeking
Retail Inkjet Solutions (RIS) and Boulanger are testing the InkCenter® ink cartridge refill service at Boulanger stores26.3.2019 14:12:00 CET | Pressemelding
CARLSBAD, Calif., March 26, 2019 (GLOBE NEWSWIRE) -- Retail Inkjet Solutions (RIS), in partnership with Boulanger, today announced a new pilot program of its ink cartridge refill service at several Boulanger retail stores. Over time, all customers of Boulanger, who specialize in home appliances and multimedia equipment, including personal and office printers, will be able to leave their empty inkjet cartridges at the Ink Bar of their local Boulanger store. While they do their shopping, a Boulanger expert advisor will refill the cartridges using the RIS InkCenter® machine, which guarantees high-quality refilling, far cheaper than buying a new cartridge. As part of this new, innovative partnership, “Ink Bars” have already opened at the following Boulanger stores: Gennevilliers, Lyon, Noyelles-Godault, Toulouse, and Toulon. “Value for money and product quality are very important for all consumers. The RIS-powered ink cartridge refill solution delivers exceptional quality ink, much more af
Wasabi Introduces Media Innovation Cloud Alliance To Deliver Disruptive Best-of-Breed Media Processing Price/Performance for Media & Entertainment26.3.2019 14:00:00 CET | Pressemelding
Next-Generation Multi-Vendor Cloud Solution Optimized For Movie/TV Production And Long-Term Archival Storage Boston, MA, March 26, 2019 (GLOBE NEWSWIRE) -- Wasabi, the hot cloud storage company, announces the Media Innovation Cloud Alliance, a coalition of best-of-breed media technology companies integrating across multiple clouds to deliver a price/performance ratio vastly superior to first-generation cloud providers like Amazon Web Services, Microsoft Azure and Google Cloud Platform. The mission of alliance partners is to enable media companies to affordably leverage independent, next-generation cloud services as an alternative to monolithic first-generation cloud stacks. Services offered by the Alliance span the media lifecycle from content transfer and ingest, to editing and transformation, to playback and delivery, through archiving and library management. Founding Media Innovation Cloud Alliance partners include: Acembly (multi-cloud management) Archiware (backup and archive) Cin
Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) Featured in NetworkNewsWire Publication on Soaring Hemp-Based CBD Industry26.3.2019 13:30:00 CET | Pressemelding
NEW YORK, March 26, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) . To read the full editorial discussing CBD industry forecasts following the passage of the Farm Bill, visit: http://nnw.fm/Q5q5a Hemp is making a comeback thanks to the growing popularity of cannabidiol (CBD), an active ingredient found in many forms of cannabis. It’s an ingredient that companies such as Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) , a creator of plant-based health and wellness products, have been making extensive use of in recent years. The Farm Bill has been driven in large part by the growing demand for CBD. An obscure and seldom discussed chemical a decade ago, CBD has emerged as an important consumer product. … Identified as a chemical with great potential for health and wellness, CBD has started to be marketed in
Bhang Corporation’s Scott Van Rixel and Jamie Pearson Named to High Times' Most Influential People in Cannabis26.3.2019 11:00:00 CET | Pressemelding
LOS ANGELES, March 26, 2019 (GLOBE NEWSWIRE) -- Bhang Corporation ("Bhang" or the "Company"), the global cannabis house of brands with an extensive, award-winning portfolio of products, is proud to announce that Bhang CEO Scott Van Rixel and COO Jamie Pearson have each been recognized by High Times Magazine for their work in the cannabis industry. Scott Van Rixel has been named to the 2018 High Times’ List of 100 Most Influential People in the Cannabis Industry and Jamie Pearson has been named one of the 2018 High Times Women of Weed, Most Influential Women in Cannabis List. “We are honored to receive these accolades from High Times” said Scott Van Rixel, CEO of Bhang. “When I started Bhang 9 years ago, I did it with the goal of creating quality and consistent products that consumers love. Today, we are one of the most recognized cannabis brand houses on the planet and I thank all our employees who work tirelessly each day to make this possible.” "I am proud to lead a passionate, execu
Nasdaq, Inc. Prices €600 Million Senior Notes Offering25.3.2019 20:07:00 CET | Pressemelding
NEW YORK, March 25, 2019 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (the “Company”) (Nasdaq: NDAQ) today announced that it priced a public offering of €600,000,000 aggregate principal amount of 1.75% senior notes due 2029 (the “Offering”). The Company expects to use the net proceeds from the Offering to refinance indebtedness and for other general corporate purposes. J.P. Morgan Securities plc, Merrill Lynch International, Mizuho International plc and Skandinaviska Enskilda Banken AB (publ) are acting as joint book-running managers for the Offering. HSBC Bank plc, ICBC Standard Bank Plc, Nordea Bank Abp, The Toronto-Dominion Bank and Wells Fargo Securities International Limited are acting as co-managers for the Offering. The Offering is being made pursuant to an effective shelf registration statement, previously filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”). Before investing, you should read the prospectus supplement and accompanying prospectus, as well as oth